-
公开(公告)号：WO1993000407A1
公开(公告)日：1993-01-07
申请号：PCT/US1992005148
申请日：1992-06-17
Applicant: NEW ENGLAND DEACONESS HOSPITAL CORPORATION
IPC: C09B01/16
CPC classification number: D06P3/26 , A61K47/6425 , A61K47/643 , A61L27/54 , A61L33/0011 , A61L33/0029 , A61L33/0047 , A61L2300/104 , A61L2300/252 , A61L2300/406 , A61L2300/442 , D06M16/00 , D06P3/54
Abstract: Disclosed is a treated material including a base material such as an extrudate, a woven fabric, or unwoven fibers, a disperse dye-type molecule such as a dye or antibiotic dispersed within and non-covalently adhered to the base material, and a molecule-of-interest immobilized on the base material by way of a reactive group on the disperse dye-type molecule. Also disclosed are methods of producing the treated material.
Abstract translation: 公开了一种处理材料，其包括基材，例如挤出物，机织织物或非织造纤维，分散染料型分子如染料或抗生素分散在非共价附着于基材上，分子 - 通过在分散染料型分子上的反应性基团固定在基材上。 还公开了生产经处理的材料的方法。
-
公开(公告)号：WO1992005749A1
公开(公告)日：1992-04-16
申请号：PCT/US1991005353
申请日：1991-07-29
Applicant: NEW ENGLAND DEACONESS HOSPITAL CORPORATION
IPC: A61F02/00
CPC classification number: A61K47/643 , A61K47/6425
Abstract: Disclosed is a soluble, biocompatible, pharmacological agent for inhibiting thrombin generation and thrombus formation, and methods for producing the same. The pharmacological agent or conjugate includes a soluble, biocompatible carrier and a thrombogenesis inhibitor immobilized thereto via a component of the carrier which binds the inhibitor. The thrombogenesis inhibitor is other than hirudin, or an active analog or active fragment of the inhibitor. The inhibitor may be bound to the component of the carrier via a bifunctional cross-linking reagent.
Abstract translation: 公开了用于抑制凝血酶产生和血栓形成的可溶性，生物相容性药理学试剂及其制备方法。 药理学试剂或缀合物包括通过结合抑制剂的载体组分固定于其上的可溶性生物相容性载体和血栓发生抑制剂。 血栓形成抑制剂不是水蛭素，还是抑制剂的活性类似物或活性片段。 抑制剂可以通过双功能交联剂与载体的组分结合。
-
公开(公告)号：WO1992005748A1
公开(公告)日：1992-04-16
申请号：PCT/US1991005352
申请日：1991-07-29
Applicant: NEW ENGLAND DEACONESS HOSPITAL CORPORATION
IPC: A61F02/00
CPC classification number: A61L33/0029 , A61K38/58 , A61K47/6425 , A61L33/128 , Y10S530/81 , Y10S530/812 , Y10S530/813
Abstract: Disclosed is a soluble, biocompatible, pharmacological agent for inhibiting thrombin generation and thrombus formation, and methods for producing the same. The pharmacological agent or conjugate includes a soluble, biocompatible carrier and a thrombogenesis inhibitor immobilized thereto via a component of the carrier which binds the inhibitor. The thrombogenesis inhibitor is hirudin, or an active analog or active fragment thereof. The thrombogenesis inhibitor may be bound to the component of the carrier via a bifunctional cross-linking reagent.
Abstract translation: 公开了用于抑制凝血酶产生和血栓形成的可溶性，生物相容性药理学试剂及其制备方法。 药理学试剂或缀合物包括通过结合抑制剂的载体组分固定于其上的可溶性生物相容性载体和血栓发生抑制剂。 血栓形成抑制剂是水蛭素或其活性的类似物或活性片段。 血栓形成抑制剂可以通过双功能交联剂与载体的组分结合。
-
公开(公告)号：WO1990001305A1
公开(公告)日：1990-02-22
申请号：PCT/US1989003345
申请日：1989-08-02
Applicant: NEW ENGLAND DEACONESS HOSPITAL CORPORATION
IPC: A61F02/02
CPC classification number: A61L33/0047 , A61F2/06 , A61L33/0029
Abstract: Disclosed is a biocompatible, thromboresistant substance useful for implantable and extracorporeal devices in contact with the vascular system, and methods for producing the same. The biocompatible, thromboresistant substance comprises a synthetic, biocompatible material, at least one biocompatible base coat layer adhered to at least one surface of the material, and the thrombogenesis inhibitor thrombomodulin immobilized on the base coat layer via a component capable of binding the inhibitor without affecting its thrombogenesis-inhibiting activity.
-
-
-
Search Results
4
records
(took 0.01 seconds)
